Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
APPH Stock Overview
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany.
Apontis Pharma Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €13.30 |
52 Week High | €27.30 |
52 Week Low | €10.60 |
Beta | 0 |
1 Month Change | 3.91% |
3 Month Change | -16.88% |
1 Year Change | -24.86% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -29.44% |
Recent News & Updates
Shareholder Returns
APPH | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -5.0% | 5.6% | -0.1% |
1Y | -24.9% | 14.2% | -12.9% |
Return vs Industry: APPH underperformed the German Pharmaceuticals industry which returned 12.5% over the past year.
Return vs Market: APPH underperformed the German Market which returned -13.3% over the past year.
Price Volatility
APPH volatility | |
---|---|
APPH Average Weekly Movement | 8.8% |
Pharmaceuticals Industry Average Movement | 6.7% |
Market Average Movement | 6.3% |
10% most volatile stocks in DE Market | 10.7% |
10% least volatile stocks in DE Market | 3.5% |
Stable Share Price: APPH is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: APPH's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 148 | Karlheinz Gast | https://apontis-pharma.de |
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company is headquartered in Monheim am Rhein, Germany.
Apontis Pharma Fundamentals Summary
APPH fundamental statistics | |
---|---|
Market Cap | €113.05m |
Earnings (TTM) | -€745.24k |
Revenue (TTM) | €51.18m |
2.2x
P/S Ratio-151.7x
P/E RatioIs APPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
APPH income statement (TTM) | |
---|---|
Revenue | €51.18m |
Cost of Revenue | €17.40m |
Gross Profit | €33.79m |
Other Expenses | €34.53m |
Earnings | -€745.24k |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | -0.088 |
Gross Margin | 66.01% |
Net Profit Margin | -1.46% |
Debt/Equity Ratio | 0.0% |
How did APPH perform over the long term?
See historical performance and comparisonValuation
Is Apontis Pharma undervalued compared to its fair value and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: APPH (€13.3) is trading below our estimate of fair value (€127.81)
Significantly Below Fair Value: APPH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: APPH is unprofitable, so we can't compare its PE Ratio to the German Pharmaceuticals industry average.
PE vs Market: APPH is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate APPH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: APPH is overvalued based on its PB Ratio (2.8x) compared to the DE Pharmaceuticals industry average (2.6x).
Future Growth
How is Apontis Pharma forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score
4/6Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
46.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.05%).
Earnings vs Market: APPH is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: APPH's is expected to become profitable in the next 3 years.
Revenue vs Market: APPH's revenue (15.9% per year) is forecast to grow faster than the German market (4.8% per year).
High Growth Revenue: APPH's revenue (15.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: APPH's Return on Equity is forecast to be low in 3 years time (13.9%).
Past Performance
How has Apontis Pharma performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
37.0%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: APPH is currently unprofitable.
Growing Profit Margin: APPH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if APPH's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare APPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.1%).
Return on Equity
High ROE: APPH has a negative Return on Equity (-1.83%), as it is currently unprofitable.
Financial Health
How is Apontis Pharma's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: APPH's short term assets (€38.0M) exceed its short term liabilities (€10.0M).
Long Term Liabilities: APPH's short term assets (€38.0M) exceed its long term liabilities (€3.4M).
Debt to Equity History and Analysis
Debt Level: APPH is debt free.
Reducing Debt: APPH had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable APPH has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: APPH is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 66.2% per year.
Dividend
What is Apontis Pharma current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate APPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate APPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if APPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if APPH's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as APPH has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Karlheinz Gast
no data
Tenure
Mr. Karlheinz Gast serves as Chief Executive Officer at Apontis Pharma AG and serves as Chairman of the Management Board. He is active in the industry since 1986 and holding the following company positions...
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Apontis Pharma AG's employee growth, exchange listings and data sources
Key Information
- Name: Apontis Pharma AG
- Ticker: APPH
- Exchange: DB
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €113.050m
- Shares outstanding: 8.50m
- Website: https://apontis-pharma.de
Number of Employees
Location
- Apontis Pharma AG
- Alfred-Nobel-Str. 10
- Monheim am Rhein
- North Rhine-Westphalia
- 40789
- Germany
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/20 00:00 |
End of Day Share Price | 2022/05/19 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.